Free tool
FAERS Monitor: Evrysdi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219285 or its brand name (Evrysdi, Risdiplam). Reports on generic versions are filed under their own applications.
Reports
4,186
Serious
1,909
46% of reports
Hospitalization
893
Death reported
437
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event356
- diarrhoea300
- asthenia230
- pneumonia225
- death215
- pyrexia186
- fatigue162
- vomiting149
- muscular weakness146
- drug ineffective140
- rash114
- headache111
- covid-19110
- nausea108
- off label use98
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 3 |
| 2020 | 137 |
| 2021 | 594 |
| 2022 | 559 |
| 2023 | 698 |
| 2024 | 1,378 |
| 2025 | 483 |
| 2026 | 334 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,973 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| no adverse eventSignal | 356 | 9.9 | 9.0 | 2,855 |
| muscular weaknessSignal | 146 | 6.5 | 5.5 | 671 |
| pneumoniaSignal | 225 | 3.5 | 3.1 | 404 |
| covid-19Signal | 110 | 3.2 | 2.6 | 161 |
| astheniaSignal | 230 | 3.1 | 2.7 | 326 |
| pyrexiaSignal | 186 | 2.7 | 2.3 | 201 |
| diarrhoeaSignal | 300 | 2.3 | 2.1 | 235 |
| vomiting | 149 | 1.6 | 1.4 | 33 |
| rash | 114 | 1.3 | 1.1 | 8 |
| death | 215 | 1.3 | 1.1 | 11 |
| fatigue | 162 | 1.0 | 0.9 | 0 |
| headache | 111 | 0.9 | 0.7 | 1 |
| nausea | 108 | 0.7 | 0.6 | 16 |
| off label use | 98 | 0.6 | 0.5 | 34 |
| drug ineffective | 140 | 0.5 | 0.5 | 60 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.